Anemia and HIV in the antiretroviral era: Potential significance of testosterone

AIDS Research and Human Retroviruses

Volumn 21, Issue 3, 2005, Pages 200-206

  Behler, Caroline ^a,b   Shade, Starley ^a   Gregory, Kellan ^a   Abrams, Donald ^a   Volberding, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; ERYTHROPOIETIN; GANCICLOVIR; STAVUDINE; TESTOSTERONE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CHRONIC DISEASE; COMORBIDITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOENDOTHELIAL SYSTEM; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ADULT; ANEMIA; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 16444377200     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.200     Document Type: Article

References (35)

1. CoyIe T: Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997;81:449-470.
2. Sullivan PS, Hanson DL, Chu SY, et al.: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV Disease Surveillance Project. Blood 1998;91:301-308.
3. Moore RD and Forney D: Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;19:54-57.
4. Semba RD, Shah N, and Vlahov D: Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:315-319.
5. Breitbart W, McDonald MV, Rosenfeld B, et al.: Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998;15:159-167.
6. Volberding P: The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl.2):S110- 114.
7. Saah AJ, Hoover DR, He Y, et al.: Factors influencing survival after AIDS: Report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-295.
8. Moore RD, Keruly JC, and Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29-33.
9. Mocroft A, Kifk O, Barton SE, et al.: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999;13:943-950.
10. Semba RD, Shah N, Klein RS, et al.: Prevalence and cumulative incidence of and risk factors for anemia in a Multicenter Cohort Study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002;34:260-266.
11. Volberding P, for The Anemia in HIV Working Group: Consensus statement: Anemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther 2000;22:1004-1020.
12. Abrams DI, Steinhart C, Frascino R: Epoetin Alfa therapy for anaemia in HIV-infected patients: Impact on quality of life. Int J STD AIDS 2000;11:659-665.
13. Revicki DA, Brown RE, Henry DH, et al.: Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994;7:474-484.
14. Henry DH, Gildon NB, Benson CA, et al.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Intern Med 1992;117:739-748.
15. Means RT: Advances in the anemia of chronic disease. Int J Hematol 1999;70:7-12.
16. Means RT and Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-1647.
17. Hambleton J: Hematologic complications of HIV infection. Oncology 1996;10:671-680.
18. Claster S: Biology of anemia, differential diagnosis and treatment options in human immunodeficiency virus infection. J Infect Dis 2002;185(Suppl. 2):S105-109.
19. Bain BJ: Pathogenesis and pathophysiology of anemia in HIV infection. Curr Opin Hematol 1999;6:89-93.
20. Dobs AS, Dempsey MA, Ladenson PW, et al.: Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84:611-616.
21. Coodley GO, Loveless MO, Nelson HD, et al.: Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr 1994;7:46-51.
22. Rietschel P, Corcoran C, Stanley T, et al.: Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240-1244.
23. Dobs A and Brown T: Metabolic abnormalities in HIV disease and injection drug use. J Acquir Immune Defic Syndr 2002;31(Suppl. 2):S70-77.
24. Grinspoon S, Corcoran C, Anderson E, et al.: Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999;28:634-636.
25. Bhasin S, Storer TW, Asbel-Sethi N, et al.: Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998;83:3155-3162.
26. Navarro JF and Mora C: Androgen therapy for anemia in elderly uremic patients. Int Urol Nephrol 2001;32:549-557.
27. Udupa KB, Crabtree HM, and Lipschitz DA: In vitro culture of proerythroblasts: Characterization of proliferative response to erythropoietin and steroids. Br J Haematol 1986;62(4): 705-714.
28. Modder B, Foley JE, and Fisher JW: The in vitro and in vivo effects of testosterone and steroid metabolites on erythroid colony forming cells (CFU-E). J Pharmacol Exp Ther 1978;207:1004-1012.
29. Ohno Y and Fisher JW: Effects of androgens on burst forming units (BFU-E) in normal rabbit bone marrows. Life Sci 1978;22:2031-2036.
30. Urabe A, Sassa S, and Kappas A: The influence of steroid hormone metabolites on the in vitro development of erythroid colonies derived from human bone marrow. J Exp Med 1979;149:1314-1325.
31. Claustres M and Sultan C: Androgen and erythropoiesis: Evidence for an androgen receptor in erythroblasts from human bone marrow cultures. Horm Res 1988;29:17-22.
32. Gardner FH and Besa EC: Physiologic mechanisms and the hematopoietic effects of the androstanes and their derivatives. Curr Top Hematol 1983;4:123-195.
33. Levine AM, Berhane K, Masri-Lavine L, et al.: Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2000;26:28-35.
34. Lawrence IG, Price DE, Howlett TA, et al.: Erythropoietin and sexual dysfunction. Nephrol Dial Transplant 1997;12(4):741-747.
35. Ballal SH, Domoto DT, Polack DC, et al.: Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991;17:29-33.